C.CampbellK.SmythP.FernndezM.et al (2018)
Some patients may wish to take a "drug holiday" after extended treatment, though the evidence supporting this approach is limited, and the risks of weight regain should be thoroughly discussed
Younossi Clinical and Translational Gastroenterology .2025
Key Active Ingredients & Skin Benefits Tranexamic Acid is a powerful brightening ingredient that helps to: Reduce the appearance of hyperpigmentation Improve uneven skin tone Support clearer, more uniform skin Enhance overall skin brightness when delivered via microneedling Niacinamide (Vitamin B3) Niacinamide is a multifunctional skin-strengthening ingredient that helps to: Improve skin barrier function Reduce redness and inflammation Balance oil production Refine pores and improve overall skin texture Glutathione Glutathione is a potent antioxidant that helps to: Brighten dull, tired-looking skin Support detoxification at a cellular level Protect against oxidative stress Promote a more radiant complexion Vitamin C Vitamin C is a powerful antioxidant that plays a key role in: Brightening the complexion Supporting collagen synthesis Improving uneven skin tone and pigmentation Protecting the skin from environmental stressors Treatment Benefits Professional microneedling serum for facial treatments Supports brighter, clearer, more even-toned skin Enhances skin radiance and luminosity Ideal for pigmentation-focused microneedling protocols Suitable for a wide range of skin types Pack Size & Treatment Yield 5 x 5ml sterile vials Up to 10 clients per box For professional microneedling use only Full Ingredient List Aqua (Water), Sodium Chloride, 1,2-Hexanediol, Ethylhexylglycerin, Butylene Glycol, Glycerin, Hydroxydecyl Ubiquinone, Hydrogenated Lecithin, Glycine Soja (Soybean) Sterols, Caprylic/Capric Triglyceride, PEG-40 Castor Oil, Tranexamic Acid, 3-O-Ethyl Ascorbic Acid, Ascorbic Acid, Niacinamide (Vitamin B3), Glutathione, Thiamine HCI (Vitamin B1), Dipotassium Glycyrrhizate, Proline, sh-Polypeptide-51, sh-Polypeptide-60.
Cell (2008) 135:82537
Click here for an overview of GLP-1 agonists for MASLD and MASH
